Similar Papers

Paper Title
Journal
Date
Author
Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia
Lorenzo Falchi ... Jorge E Cortes
Blood | VOL. 120
Lorenzo Falchi, et. al.Lorenzo Falchi ... Jorge E Cortes
16 Nov 2012
Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia
Mahesh Swaminathan ... Jorge E Cortes
Blood | VOL. 132
Mahesh Swaminathan, et. al.Mahesh Swaminathan ... Jorge E Cortes
29 Nov 2018
Patients' and Physicians' Concerns about Tyrosine Kinase-Inhibitor Therapy in Chronic Myeloid Leukemia
Qian Jiang ... Robert Peter Gale
Blood | VOL. 128
Qian Jiang, et. al.Qian Jiang ... Robert Peter Gale
02 Dec 2016
Decision letter: Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy
Jesse A Sharp ... Aleksandra M Walczak
-
Jesse A Sharp, et. al.Jesse A Sharp ... Aleksandra M Walczak
16 Jan 2023
View more papers

More From: Future oncology (London, England)

Paper Title
Journal
Date
Author
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).
Ciara Conduit ...
Future oncology (London, England) | VOL. -
Ciara Conduit, et. al.Ciara Conduit ...
17 Jan 2025
Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer.
Ritu Salani ... Floor J Backes
Future oncology (London, England) | VOL. -
Ritu Salani, et. al.Ritu Salani ... Floor J Backes
17 Jan 2025
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.
Kevin Harrington ... Patricia Lorusso
Future oncology (London, England) | VOL. -
Kevin Harrington, et. al.Kevin Harrington ... Patricia Lorusso
16 Jan 2025
Prevalence of medical conditions or comorbidities influencing first-line therapy in unresectable hepatocellular carcinoma in the United States.
Tammy A Schuler ... Bruce Feinberg
Future oncology (London, England) | VOL. -
Tammy A Schuler, et. al.Tammy A Schuler ... Bruce Feinberg
15 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.